STAT6 Degradation: A Novel Oral Target for Asthma?

At the European Respiratory Society (ERS) Congress 2026 in Barcelona, Spain, held September 5 to 9, one of the more forward-looking conversations in the severe asthma track centered not on a new biologic or an approval, but on a transcription factor: signal transducer and activator of transcription 6 (STAT6), the intracellular convergence point for interleukin (IL)-4 and IL-13 signaling. The emerging interest reflects a therapeutic proposition that would have been difficult to imagine a few years ago — an oral small molecule capable of reproducing, at least mechanistically, what injectable type 2–targeted biologics accomplish, and doing so at a step in the inflammatory cascade that no approved asthma therapy currently reaches.

STAT6 sits downstream of the IL-4 receptor alpha subunit, the receptor that dupilumab blocks to inhibit both IL-4 and IL-13 signaling. Once activated, STAT6 translocates to the nucleus and drives transcription of the genes underlying type 2 inflammation. Blocking or removing STAT6, in principle, interrupts that program regardless of how much upstream cytokine is present.

"STAT6, it's really a great molecule. It's a key intracellular signaling protein that is involved in type 2 pathways, especially the IL-4/IL-13 pathway," Florence Schleich, MD, PhD, a respiratory physician at the University of Liège in Belgium, told HCPLive. "If you block STAT6, it's an intracellular blockade, because STAT6 is going into the nucleus and inducing the transcription of the inflammatory genes for type 2 inflammation. So it's a great opportunity to have a new target in the future."

A Downstream Mechanism in an Upstream Era?

Much of the recent innovation in obstructive airway disease has moved toward the epithelial alarmins — thymic stromal lymphopoietin (TSLP) and IL-33 — which act at the top of the inflammatory cascade. STAT6 degradation moves in the opposite direction, intervening well downstream of those signals.

"Oral STAT6 degraders work further downstream compared to the epithelial alarmin targeted therapies like ones that target TSLP or IL-33," said Michael E. Wechsler, MD, MMSc, of National Jewish Health in Denver, Colorado. "The STAT6 degraders work downstream and degrade some of the downstream signaling pathways mediated by Janus-activated kinases and STAT6 and STAT5, for example."

The rationale for pursuing STAT6 in asthma has been built substantially on early data from atopic dermatitis, another type 2–driven disease. "The STAT6 degrader that you were talking about has been shown to be effective in atopic dermatitis, and there's reason to believe that it may be effective in asthma as well," Wechsler said. "One of the benefits of that therapy is that it's an oral therapy, and because some patients prefer to take pills, this may have beneficial effects as well."

The degrader drawing the most attention is Kymera Therapeutics' KT-621, described by the company as a first-in-class, once-daily oral degrader of STAT6.^¹ In the 22-participant phase 1b BroADen trial in moderate-to-severe atopic dermatitis, KT-621 achieved median STAT6 reductions of 94% in skin and 98% in blood across the 100 mg and 200 mg dose groups, alongside a mean 63% reduction in Eczema Area and Severity Index (EASI) scores and a 40% reduction in peak pruritus numerical rating scale scores at 4 weeks, with no treatment-related adverse events reported.^¹² Notably for the airway field, participants with comorbid asthma showed a median 56% reduction in fractional exhaled nitric oxide (FeNO).^¹ Kymera has since advanced KT-621 into parallel phase 2b trials — BROADEN2 in atopic dermatitis and BREADTH in asthma — with asthma data expected in late 2027, and the US Food and Drug Administration has granted the program Fast Track designation in both moderate-to-severe atopic dermatitis and moderate-to-severe asthma.^³ These are early-phase and largely company-reported findings, and the atopic dermatitis results have not yet been evaluated in a phase 3 asthma population.

Wechsler was measured on that distance. "There's a long way to go from being a concept in atopic dermatitis to moving past phase three and into the FDA and getting approval, but I think based on the mechanism, there's a strong rationale for it. Based on the preliminary data in atopic dermatitis, there's a strong rationale for it as well."

Where Might an Oral Agent Fit?

The clinical interest in STAT6 degradation is less about displacing existing biologics than about reaching patients those biologics do not. Njira Lugogo, MD, professor of medicine and asthma program director at the University of Michigan in Ann Arbor, framed the pathway as a way to potentially deliver a biologic-like effect through an oral route.

"Your IL-4 and 13 downstream inflammatory effects are modulated via STAT6," Lugogo said. "Before you get to the production of the inflammatory proteins, you have STAT6 as the common pathway for IL-4 and 13. So, theoretically, targeting STAT6 should inhibit both IL-4 and 13 effects. Our only current drug that inhibits IL-4 and 13 simultaneously is dupilumab by blocking the IL-4 receptor alpha, which is the predominant effector receptor for IL-13. So we could imagine a time where we have an oral drug that has the ability to replicate what we're doing with biologics, and that really opens the space entirely."

Lugogo outlined several distinct positions an oral STAT6 degrader might occupy. The first is dual targeted therapy for partial responders. "Could STAT6 inhibition be a way to achieve dual targeted therapy? That's a potential option where patients are already on a biologic and perhaps not fully responding," she said, pointing specifically to partial responders and those with discordant upper and lower airway disease.

The second is a pre-biologic role, particularly where access is a barrier. "Could it be a pre-biologic? Potentially patients who you're thinking need to go on biologic, you've maximized inhaled therapy, you're not quite so sure that you want to use a biologic or the patient can't use a biologic," Lugogo said. "There are really quite a few places in the world where biologic penetrance is so poor because of all the logistical issues, the cold chain delivery, and so forth, so could an oral agent in that population be an option?"

A third potential use is early intervention in high-risk populations, an area of growing research interest across several mechanisms. Lugogo noted that an oral therapy "could be used in a wider population, maybe more accessible" for the kind of early-intervention trials the field increasingly wants to run.

Finally, she raised an inhaled corticosteroid (ICS)–sparing role, framed against ongoing efforts to reduce high-dose ICS exposure. "There is a huge focus on inhaled corticosteroid safety and mitigating that, reducing high-dose inhaled corticosteroid exposure. That therefore allows us to rethink whether we could have STAT6 therapy as an add-on and ICS-sparing therapy."

The through-line across all 4 scenarios is access. "The majority of asthma patients really can't access targeted therapy. Currently, it's for the most severe population," Lugogo said. "As we want to expand the population and really improve outcomes, I can envision this as being just a really amazing way to expand the population and hopefully achieve a biologic-like response in those patients."

Open Questions?

The enthusiasm is consistently paired with caution, and the caution centers on safety — an unavoidable consideration for any oral agent that suppresses an intracellular signaling node systemically. Schleich noted that the safety profile, once mature, could shape the route of administration itself.

"We will have to see the data, especially regarding safety," Schleich said. "If there are safety concerns, could move to inhalation treatment, inhalation anti-STAT6 treatment, as we did for ICS, because there were side effects with OCS. Could be a good way to move on to inhalation therapy, but it's pure speculation for the future."

That unmet need is what keeps the pathway compelling despite its early stage. As Wechsler noted, remission remains elusive for most patients even in the biologic era. "For patients with asthma, we're doing a good job of getting some people into remission, but really only 25 to 40% of patients get into remission, and that suggests that we need to give the right drugs to the right patient at the right time, and we might need other targeted strategies. So STAT6 offers a novel targeted strategy for our patients as well."

For now, STAT6 degradation remains a concept validated primarily in a different organ system and awaiting its first controlled asthma readout. Lugogo, for her part, was clear about both the uncertainty and the appeal. "It's very early. It's emerging, but I think it's extremely promising, and I'm quite excited to see the direction that it goes in over the next few years."

Relevant disclosures for Schleich include AstraZeneca and GSK; Wechsler’s disclosures include Genzyme, Regeneron, AStraZeneca, GSK, and Pfizer; Lugogo’s disclosures include AbbVie, Amgen, Apogee Therapeutics, AstraZeneca, Foresee Pharmaceuticals, Genentech, GSK, Incyte, Niox, Regeneron, Sanofi and Teva Pharmaceuticals.

References

1. Kymera Therapeutics. Kymera Therapeutics announces positive results from BroADen phase 1b clinical trial of KT-621, a first-in-class, oral STAT6 degrader, in patients with moderate to severe atopic dermatitis. Press release. December 2025. Accessed September 17, 2026. https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-announces-positive-results-broaden-phase-1b

2. Kymera Therapeutics. Kymera Therapeutics presents KT-621 BroADen data in late-breaking research session at the American Academy of Dermatology (AAD) Annual Meeting. Press release. March 28, 2026. Accessed September 17, 2026. https://investors.kymeratx.com/news-releases/news-release-details/kymera-therapeutics-presents-kt-621-broaden-data-late-breaking

3. Kymera Therapeutics. Kymera Therapeutics announces first quarter 2026 financial results and provides a business update. Press release. 2026. Accessed September 17, 2026. https://firstwordpharma.com/story/7252952